{"entity":{"type":"insider","cik":"0001431159","url":"/insider/0001431159","json_url":"/insider/0001431159.json","name":"Tammenoms Bakker Juliet","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":105,"n_filings":53,"first":"2009-02-10","last":"2026-02-06","span_basis":"filed_date"},"name_variants":[{"name":"Tammenoms Bakker Juliet","source":"filing","n_filings":53,"first_seen":"2009-02-10","last_seen":"2026-02-06"}],"transactions":[{"id":6036226,"accession":"0001193125-26-041248","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-041248","line_url":"/filing/0001193125-26-041248#line-1","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"RAPID MICRO BIOSYSTEMS, INC.","issuer_ticker":"RPID","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"ENRIGHT PATRICK G; Longitude Capital Partners II, LLC; Longitude Prime Fund, L.P.; Longitude Prime Partners, LLC; Longitude Venture Partners II, L.P.; Tammenoms Bakker Juliet","owner_display_name":"ENRIGHT PATRICK G","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":49000.0,"shares_display":"49,000","price_per_share":3.8794,"price_display":"3.88","price_state":"stated","total_value":190090.6,"total_display":"190,090.60","total_whole":"190,091","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-02-04","filed_date":"2026-02-06","scope":"insider"},{"id":6036159,"accession":"0001193125-26-036387","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001193125-26-036387","line_url":"/filing/0001193125-26-036387#line-5","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"RAPID MICRO BIOSYSTEMS, INC.","issuer_ticker":"RPID","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"ENRIGHT PATRICK G; Longitude Capital Partners II, LLC; Longitude Prime Partners, LLC; Longitude Venture Partners II, L.P.; Tammenoms Bakker Juliet","owner_display_name":"ENRIGHT PATRICK G","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":27500.0,"shares_display":"27,500","price_per_share":4.2415,"price_display":"4.24","price_state":"stated","total_value":116641.25,"total_display":"116,641.25","total_whole":"116,641","shares_owned_after":49000.0,"shares_owned_after_display":"49,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-02-03","filed_date":"2026-02-03","scope":"insider"},{"id":6036156,"accession":"0001193125-26-036387","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193125-26-036387","line_url":"/filing/0001193125-26-036387#line-4","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"RAPID MICRO BIOSYSTEMS, INC.","issuer_ticker":"RPID","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"ENRIGHT PATRICK G; Longitude Capital Partners II, LLC; Longitude Prime Partners, LLC; Longitude Venture Partners II, L.P.; Tammenoms Bakker Juliet","owner_display_name":"ENRIGHT PATRICK G","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":27500.0,"shares_display":"27,500","price_per_share":4.246,"price_display":"4.25","price_state":"stated","total_value":116765.0,"total_display":"116,765.00","total_whole":"116,765","shares_owned_after":76500.0,"shares_owned_after_display":"76,500","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-02-02","filed_date":"2026-02-03","scope":"insider"},{"id":6036153,"accession":"0001193125-26-036387","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193125-26-036387","line_url":"/filing/0001193125-26-036387#line-3","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"RAPID MICRO BIOSYSTEMS, INC.","issuer_ticker":"RPID","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"ENRIGHT PATRICK G; Longitude Capital Partners II, LLC; Longitude Prime Partners, LLC; Longitude Venture Partners II, L.P.; Tammenoms Bakker Juliet","owner_display_name":"ENRIGHT PATRICK G","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":46000.0,"shares_display":"46,000","price_per_share":4.5435,"price_display":"4.54","price_state":"stated","total_value":209001.0,"total_display":"209,001.00","total_whole":"209,001","shares_owned_after":104000.0,"shares_owned_after_display":"104,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-01-30","filed_date":"2026-02-03","scope":"insider"},{"id":6036146,"accession":"0001193125-26-036387","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-036387","line_url":"/filing/0001193125-26-036387#line-1","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"RAPID MICRO BIOSYSTEMS, INC.","issuer_ticker":"RPID","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"ENRIGHT PATRICK G; Longitude Capital Partners II, LLC; Longitude Prime Partners, LLC; Longitude Venture Partners II, L.P.; Tammenoms Bakker Juliet","owner_display_name":"ENRIGHT PATRICK G","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7739.0,"shares_display":"7,739","price_per_share":4.064,"price_display":"4.06","price_state":"stated","total_value":31451.296,"total_display":"31,451.30","total_whole":"31,451","shares_owned_after":4029245.0,"shares_owned_after_display":"4,029,245","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-01-23","filed_date":"2026-02-03","scope":"insider"},{"id":2083223,"accession":"0000950170-24-115007","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-115007","line_url":"/filing/0000950170-24-115007#line-3","is_derivative":false,"issuer_cik":"0001431159","issuer_name":"Ceribell, Inc.","issuer_ticker":"CBLL","issuer_name_source":null,"issuer_url":"/issuer/0001431159","owner_cik":"0001431159","owner_name":"Tammenoms Bakker Juliet","owner_display_name":"Tammenoms Bakker Juliet","owner_url":"/insider/0001431159","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":237234.0,"shares_display":"237,234","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":4032978.0,"total_display":"4,032,978.00","total_whole":"4,032,978","shares_owned_after":2475110.0,"shares_owned_after_display":"2,475,110","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-10-15","filed_date":"2024-10-16","scope":"insider"},{"id":2636941,"accession":"0000950170-24-062883","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-062883","line_url":"/filing/0000950170-24-062883#line-1","is_derivative":false,"issuer_cik":"0001111485","issuer_name":"RxSight, Inc.","issuer_ticker":"RXST","issuer_name_source":null,"issuer_url":"/issuer/0001111485","owner_cik":"0001431159","owner_name":"Tammenoms Bakker Juliet","owner_display_name":"Tammenoms Bakker Juliet","owner_url":"/insider/0001431159","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":61.0913,"price_display":"61.09","price_state":"stated","total_value":305456.5,"total_display":"305,456.50","total_whole":"305,457","shares_owned_after":34840.0,"shares_owned_after_display":"34,840","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-17","filed_date":"2024-05-21","scope":"insider"},{"id":3071536,"accession":"0000950170-24-015900","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-015900","line_url":"/filing/0000950170-24-015900#line-2","is_derivative":false,"issuer_cik":"0001111485","issuer_name":"RxSight, Inc.","issuer_ticker":"RXST","issuer_name_source":null,"issuer_url":"/issuer/0001111485","owner_cik":"0001431159","owner_name":"Tammenoms Bakker Juliet","owner_display_name":"Tammenoms Bakker Juliet","owner_url":"/insider/0001431159","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4000.0,"shares_display":"4,000","price_per_share":51.2883,"price_display":"51.29","price_state":"stated","total_value":205153.2,"total_display":"205,153.20","total_whole":"205,153","shares_owned_after":29840.0,"shares_owned_after_display":"29,840","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-14","filed_date":"2024-02-15","scope":"insider"},{"id":3071529,"accession":"0000950170-24-015900","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-015900","line_url":"/filing/0000950170-24-015900#line-1","is_derivative":false,"issuer_cik":"0001111485","issuer_name":"RxSight, Inc.","issuer_ticker":"RXST","issuer_name_source":null,"issuer_url":"/issuer/0001111485","owner_cik":"0001431159","owner_name":"Tammenoms Bakker Juliet","owner_display_name":"Tammenoms Bakker Juliet","owner_url":"/insider/0001431159","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4000.0,"shares_display":"4,000","price_per_share":50.3799,"price_display":"50.38","price_state":"stated","total_value":201519.6,"total_display":"201,519.60","total_whole":"201,520","shares_owned_after":25840.0,"shares_owned_after_display":"25,840","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-12","filed_date":"2024-02-15","scope":"insider"},{"id":8646291,"accession":"0000950170-23-067110","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-23-067110","line_url":"/filing/0000950170-23-067110#line-2","is_derivative":false,"issuer_cik":"0001111485","issuer_name":"RxSight, Inc.","issuer_ticker":"RXST","issuer_name_source":null,"issuer_url":"/issuer/0001111485","owner_cik":"0001431159","owner_name":"Tammenoms Bakker Juliet","owner_display_name":"Tammenoms Bakker Juliet","owner_url":"/insider/0001431159","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":349245.0,"shares_display":"349,245","price_per_share":29.7747,"price_display":"29.77","price_state":"stated","total_value":10398665.1015,"total_display":"10,398,665.10","total_whole":"10,398,665","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-29","filed_date":"2023-11-30","scope":"insider"},{"id":8646289,"accession":"0000950170-23-067110","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-23-067110","line_url":"/filing/0000950170-23-067110#line-1","is_derivative":false,"issuer_cik":"0001111485","issuer_name":"RxSight, Inc.","issuer_ticker":"RXST","issuer_name_source":null,"issuer_url":"/issuer/0001111485","owner_cik":"0001431159","owner_name":"Tammenoms Bakker Juliet","owner_display_name":"Tammenoms Bakker Juliet","owner_url":"/insider/0001431159","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":145068.0,"shares_display":"145,068","price_per_share":29.6208,"price_display":"29.62","price_state":"stated","total_value":4297030.2144,"total_display":"4,297,030.21","total_whole":"4,297,030","shares_owned_after":349245.0,"shares_owned_after_display":"349,245","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-28","filed_date":"2023-11-30","scope":"insider"},{"id":7857821,"accession":"0000950170-23-064616","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-23-064616","line_url":"/filing/0000950170-23-064616#line-2","is_derivative":false,"issuer_cik":"0001111485","issuer_name":"RxSight, Inc.","issuer_ticker":"RXST","issuer_name_source":null,"issuer_url":"/issuer/0001111485","owner_cik":"0001431159","owner_name":"Tammenoms Bakker Juliet","owner_display_name":"Tammenoms Bakker Juliet","owner_url":"/insider/0001431159","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400000.0,"shares_display":"400,000","price_per_share":27.1954,"price_display":"27.20","price_state":"stated","total_value":10878160.0,"total_display":"10,878,160.00","total_whole":"10,878,160","shares_owned_after":494313.0,"shares_owned_after_display":"494,313","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-15","filed_date":"2023-11-16","scope":"insider"},{"id":7857816,"accession":"0000950170-23-064616","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-23-064616","line_url":"/filing/0000950170-23-064616#line-1","is_derivative":false,"issuer_cik":"0001111485","issuer_name":"RxSight, Inc.","issuer_ticker":"RXST","issuer_name_source":null,"issuer_url":"/issuer/0001111485","owner_cik":"0001431159","owner_name":"Tammenoms Bakker Juliet","owner_display_name":"Tammenoms Bakker Juliet","owner_url":"/insider/0001431159","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":27.1259,"price_display":"27.13","price_state":"stated","total_value":2712590.0,"total_display":"2,712,590.00","total_whole":"2,712,590","shares_owned_after":894313.0,"shares_owned_after_display":"894,313","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-14","filed_date":"2023-11-16","scope":"insider"},{"id":8296920,"accession":"0001209191-23-054904","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-23-054904","line_url":"/filing/0001209191-23-054904#line-3","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Lexeo Therapeutics, Inc.","issuer_ticker":"LXEO","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"Longitude Capital Partners IV, LLC; Longitude Venture Partners IV, L.P.; Tammenoms Bakker Juliet; ENRIGHT PATRICK G","owner_display_name":"Longitude Capital Partners IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":454545.0,"shares_display":"454,545","price_per_share":11.0,"price_display":"11.00","price_state":"stated","total_value":4999995.0,"total_display":"4,999,995.00","total_whole":"4,999,995","shares_owned_after":2567100.0,"shares_owned_after_display":"2,567,100","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-07","filed_date":"2023-11-09","scope":"insider"},{"id":8282063,"accession":"0000950170-23-047537","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-23-047537","line_url":"/filing/0000950170-23-047537#line-3","is_derivative":false,"issuer_cik":"0001111485","issuer_name":"RxSight, Inc.","issuer_ticker":"RXST","issuer_name_source":null,"issuer_url":"/issuer/0001111485","owner_cik":"0001431159","owner_name":"Tammenoms Bakker Juliet","owner_display_name":"Tammenoms Bakker Juliet","owner_url":"/insider/0001431159","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2950.0,"shares_display":"2,950","price_per_share":30.0084,"price_display":"30.01","price_state":"stated","total_value":88524.78,"total_display":"88,524.78","total_whole":"88,525","shares_owned_after":20223.0,"shares_owned_after_display":"20,223","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-11","filed_date":"2023-09-11","scope":"insider"},{"id":8282059,"accession":"0000950170-23-047537","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-23-047537","line_url":"/filing/0000950170-23-047537#line-2","is_derivative":false,"issuer_cik":"0001111485","issuer_name":"RxSight, Inc.","issuer_ticker":"RXST","issuer_name_source":null,"issuer_url":"/issuer/0001111485","owner_cik":"0001431159","owner_name":"Tammenoms Bakker Juliet","owner_display_name":"Tammenoms Bakker Juliet","owner_url":"/insider/0001431159","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10033.0,"shares_display":"10,033","price_per_share":30.2463,"price_display":"30.25","price_state":"stated","total_value":303461.1279,"total_display":"303,461.13","total_whole":"303,461","shares_owned_after":23173.0,"shares_owned_after_display":"23,173","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-08","filed_date":"2023-09-11","scope":"insider"},{"id":8282055,"accession":"0000950170-23-047537","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-23-047537","line_url":"/filing/0000950170-23-047537#line-1","is_derivative":false,"issuer_cik":"0001111485","issuer_name":"RxSight, Inc.","issuer_ticker":"RXST","issuer_name_source":null,"issuer_url":"/issuer/0001111485","owner_cik":"0001431159","owner_name":"Tammenoms Bakker Juliet","owner_display_name":"Tammenoms Bakker Juliet","owner_url":"/insider/0001431159","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":19967.0,"shares_display":"19,967","price_per_share":30.0988,"price_display":"30.10","price_state":"stated","total_value":600982.7396,"total_display":"600,982.74","total_whole":"600,983","shares_owned_after":33206.0,"shares_owned_after_display":"33,206","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-07","filed_date":"2023-09-11","scope":"insider"},{"id":7838479,"accession":"0000950170-23-044850","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-23-044850","line_url":"/filing/0000950170-23-044850#line-4","is_derivative":false,"issuer_cik":"0001111485","issuer_name":"RxSight, Inc.","issuer_ticker":"RXST","issuer_name_source":null,"issuer_url":"/issuer/0001111485","owner_cik":"0001431159","owner_name":"Tammenoms Bakker Juliet","owner_display_name":"Tammenoms Bakker Juliet","owner_url":"/insider/0001431159","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16208.0,"shares_display":"16,208","price_per_share":29.2528,"price_display":"29.25","price_state":"stated","total_value":474129.3824,"total_display":"474,129.38","total_whole":"474,129","shares_owned_after":53173.0,"shares_owned_after_display":"53,173","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-08-25","filed_date":"2023-08-28","scope":"insider"},{"id":7838457,"accession":"0000950170-23-043465","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-23-043465","line_url":"/filing/0000950170-23-043465#line-2","is_derivative":false,"issuer_cik":"0001111485","issuer_name":"RxSight, Inc.","issuer_ticker":"RXST","issuer_name_source":null,"issuer_url":"/issuer/0001111485","owner_cik":"0001431159","owner_name":"Tammenoms Bakker Juliet","owner_display_name":"Tammenoms Bakker Juliet","owner_url":"/insider/0001431159","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14651.0,"shares_display":"14,651","price_per_share":29.0681,"price_display":"29.07","price_state":"stated","total_value":425876.7331,"total_display":"425,876.73","total_whole":"425,877","shares_owned_after":68411.0,"shares_owned_after_display":"68,411","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-08-18","filed_date":"2023-08-18","scope":"insider"},{"id":7838454,"accession":"0000950170-23-043465","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-23-043465","line_url":"/filing/0000950170-23-043465#line-1","is_derivative":false,"issuer_cik":"0001111485","issuer_name":"RxSight, Inc.","issuer_ticker":"RXST","issuer_name_source":null,"issuer_url":"/issuer/0001111485","owner_cik":"0001431159","owner_name":"Tammenoms Bakker Juliet","owner_display_name":"Tammenoms Bakker Juliet","owner_url":"/insider/0001431159","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":18484.0,"shares_display":"18,484","price_per_share":30.0635,"price_display":"30.06","price_state":"stated","total_value":555693.734,"total_display":"555,693.73","total_whole":"555,694","shares_owned_after":83062.0,"shares_owned_after_display":"83,062","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-08-17","filed_date":"2023-08-18","scope":"insider"},{"id":8701429,"accession":"0001209191-23-008849","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-008849","line_url":"/filing/0001209191-23-008849#line-1","is_derivative":false,"issuer_cik":"0001111485","issuer_name":"RxSight, Inc.","issuer_ticker":"RXST","issuer_name_source":null,"issuer_url":"/issuer/0001111485","owner_cik":"0001431159","owner_name":"Tammenoms Bakker Juliet","owner_display_name":"Tammenoms Bakker Juliet","owner_url":"/insider/0001431159","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":480000.0,"shares_display":"480,000","price_per_share":12.5,"price_display":"12.50","price_state":"stated","total_value":6000000.0,"total_display":"6,000,000.00","total_whole":"6,000,000","shares_owned_after":980000.0,"shares_owned_after_display":"980,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-02-10","filed_date":"2023-02-13","scope":"insider"},{"id":7799552,"accession":"0000899243-23-004349","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-004349","line_url":"/filing/0000899243-23-004349#line-1","is_derivative":false,"issuer_cik":"0001431159","issuer_name":"Vera Therapeutics, Inc.","issuer_ticker":"VERA","issuer_name_source":null,"issuer_url":"/issuer/0001431159","owner_cik":null,"owner_name":"Tammenoms Bakker Juliet; Longitude Prime Fund, L.P.; Longitude Capital Partners IV, LLC; Longitude Prime Partners, LLC; Longitude Venture Partners IV, L.P.","owner_display_name":"Tammenoms Bakker Juliet","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1714285.0,"shares_display":"1,714,285","price_per_share":7.0,"price_display":"7.00","price_state":"stated","total_value":11999995.0,"total_display":"11,999,995.00","total_whole":"11,999,995","shares_owned_after":1714285.0,"shares_owned_after_display":"1,714,285","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-02-06","filed_date":"2023-02-08","scope":"insider"},{"id":6691184,"accession":"0000899243-22-015325","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-015325","line_url":"/filing/0000899243-22-015325#line-1","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Inozyme Pharma, Inc.","issuer_ticker":"INZY","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"Longitude Venture Partners III, L.P.; Longitude Capital Partners III, LLC; ENRIGHT PATRICK G; Tammenoms Bakker Juliet","owner_display_name":"Longitude Venture Partners III, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1355000.0,"shares_display":"1,355,000","price_per_share":3.69,"price_display":"3.69","price_state":"stated","total_value":4999950.0,"total_display":"4,999,950.00","total_whole":"4,999,950","shares_owned_after":4174379.0,"shares_owned_after_display":"4,174,379","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-04-19","filed_date":"2022-04-21","scope":"insider"},{"id":6532421,"accession":"0000899243-22-013598","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-013598","line_url":"/filing/0000899243-22-013598#line-1","is_derivative":false,"issuer_cik":"0001431159","issuer_name":"Vera Therapeutics, Inc.","issuer_ticker":"VERA","issuer_name_source":null,"issuer_url":"/issuer/0001431159","owner_cik":null,"owner_name":"Tammenoms Bakker Juliet; Longitude Capital Partners IV, LLC; Longitude Venture Partners IV, L.P.","owner_display_name":"Tammenoms Bakker Juliet","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":333333.0,"shares_display":"333,333","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":4999995.0,"total_display":"4,999,995.00","total_whole":"4,999,995","shares_owned_after":3429927.0,"shares_owned_after_display":"3,429,927","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-02-10","filed_date":"2022-04-05","scope":"insider"},{"id":6531980,"accession":"0000899243-22-004271","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-004271","line_url":"/filing/0000899243-22-004271#line-1","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Sierra Oncology, Inc.","issuer_ticker":"SRRA","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"Longitude Prime Fund, L.P.; Longitude Prime Partners, LLC; ENRIGHT PATRICK G; Tammenoms Bakker Juliet; Longitude Venture Partners III, L.P.; Longitude Capital Partners III, LLC","owner_display_name":"Longitude Prime Fund, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":175000.0,"shares_display":"175,000","price_per_share":27.0,"price_display":"27.00","price_state":"stated","total_value":4725000.0,"total_display":"4,725,000.00","total_whole":"4,725,000","shares_owned_after":175000.0,"shares_owned_after_display":"175,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-02-02","filed_date":"2022-02-02","scope":"insider"},{"id":5431711,"accession":"0000899243-21-031826","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-21-031826","line_url":"/filing/0000899243-21-031826","is_derivative":false,"issuer_cik":"0001111485","issuer_name":"RxSight, Inc.","issuer_ticker":"RXST","issuer_name_source":null,"issuer_url":"/issuer/0001111485","owner_cik":"0001431159","owner_name":"Tammenoms Bakker Juliet","owner_display_name":"Tammenoms Bakker Juliet","owner_url":"/insider/0001431159","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":637500.0,"shares_display":"637,500","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":10200000.0,"total_display":"10,200,000.00","total_whole":"10,200,000","shares_owned_after":500000.0,"shares_owned_after_display":"500,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-03","filed_date":"2021-08-05","scope":"insider","n_lines":3},{"id":4305930,"accession":"0000899243-21-029105","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-21-029105","line_url":"/filing/0000899243-21-029105#line-2","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"RAPID MICRO BIOSYSTEMS, INC.","issuer_ticker":"RPID","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"Longitude Capital Partners II, LLC; Longitude Prime Partners, LLC; ENRIGHT PATRICK G; Longitude Prime Fund, L.P.; Longitude Venture Partners II, L.P.; Tammenoms Bakker Juliet","owner_display_name":"Longitude Capital Partners II, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":150000.0,"shares_display":"150,000","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":3000000.0,"total_display":"3,000,000.00","total_whole":"3,000,000","shares_owned_after":150000.0,"shares_owned_after_display":"150,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-07-19","filed_date":"2021-07-20","scope":"insider"},{"id":5044196,"accession":"0001209191-21-033816","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-033816","line_url":"/filing/0001209191-21-033816#line-2","is_derivative":false,"issuer_cik":"0001431159","issuer_name":"Vera Therapeutics, Inc.","issuer_ticker":"VERA","issuer_name_source":null,"issuer_url":"/issuer/0001431159","owner_cik":null,"owner_name":"Longitude Venture Partners IV, L.P.; Longitude Capital Partners IV, LLC; Tammenoms Bakker Juliet","owner_display_name":"Longitude Venture Partners IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":909090.0,"shares_display":"909,090","price_per_share":11.0,"price_display":"11.00","price_state":"stated","total_value":9999990.0,"total_display":"9,999,990.00","total_whole":"9,999,990","shares_owned_after":3096594.0,"shares_owned_after_display":"3,096,594","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-05-18","filed_date":"2021-05-18","scope":"insider"},{"id":4708239,"accession":"0000899243-21-019166","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-21-019166","line_url":"/filing/0000899243-21-019166#line-2","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Talaris Therapeutics, Inc.","issuer_ticker":"TALS","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"Tammenoms Bakker Juliet; Longitude Capital Partners III, LLC; ENRIGHT PATRICK G; Longitude Venture Partners III, L.P.","owner_display_name":"Tammenoms Bakker Juliet","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":235000.0,"shares_display":"235,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":3995000.0,"total_display":"3,995,000.00","total_whole":"3,995,000","shares_owned_after":3220775.0,"shares_owned_after_display":"3,220,775","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-05-11","filed_date":"2021-05-11","scope":"insider"},{"id":2169644,"accession":"0000899243-20-029083","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-029083","line_url":"/filing/0000899243-20-029083#line-2","is_derivative":false,"issuer_cik":"0001431159","issuer_name":"Eargo, Inc.","issuer_ticker":"EAR","issuer_name_source":null,"issuer_url":"/issuer/0001431159","owner_cik":"0001431159","owner_name":"Tammenoms Bakker Juliet","owner_display_name":"Tammenoms Bakker Juliet","owner_url":"/insider/0001431159","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":233333.0,"shares_display":"233,333","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":4199994.0,"total_display":"4,199,994.00","total_whole":"4,199,994","shares_owned_after":3918691.0,"shares_owned_after_display":"3,918,691","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-10-20","filed_date":"2020-10-22","scope":"insider"},{"id":2895800,"accession":"0000899243-20-025932","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-20-025932","line_url":"/filing/0000899243-20-025932#line-1","is_derivative":false,"issuer_cik":"0001431159","issuer_name":"Axonics Modulation Technologies, Inc.","issuer_ticker":"AXNX","issuer_name_source":null,"issuer_url":"/issuer/0001431159","owner_cik":"0001431159","owner_name":"Tammenoms Bakker Juliet","owner_display_name":"Tammenoms Bakker Juliet","owner_url":"/insider/0001431159","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9167.0,"shares_display":"9,167","price_per_share":42.666,"price_display":"42.67","price_state":"stated","total_value":391119.222,"total_display":"391,119.22","total_whole":"391,119","shares_owned_after":3500.0,"shares_owned_after_display":"3,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-09-18","filed_date":"2020-09-22","scope":"insider"},{"id":3239630,"accession":"0000899243-20-023790","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-023790","line_url":"/filing/0000899243-20-023790","is_derivative":false,"issuer_cik":"0001183765","issuer_name":"Molecular Templates, Inc.","issuer_ticker":"MTEM","issuer_name_source":null,"issuer_url":"/issuer/0001183765","owner_cik":null,"owner_name":"ENRIGHT PATRICK G; Longitude Capital Partners III, LLC; Longitude Venture Partners III, L.P.; Tammenoms Bakker Juliet","owner_display_name":"ENRIGHT PATRICK G","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3496.0,"shares_display":"3,496","price_per_share":10.7461,"price_display":"10.75","price_state":"stated","total_value":37568.3656,"total_display":"37,568.37","total_whole":"37,568","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-08-28","filed_date":"2020-09-01","scope":"insider","n_lines":2},{"id":2133231,"accession":"0000899243-20-022742","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-20-022742","line_url":"/filing/0000899243-20-022742#line-1","is_derivative":false,"issuer_cik":"0001431159","issuer_name":"Axonics Modulation Technologies, Inc.","issuer_ticker":"AXNX","issuer_name_source":null,"issuer_url":"/issuer/0001431159","owner_cik":"0001431159","owner_name":"Tammenoms Bakker Juliet","owner_display_name":"Tammenoms Bakker Juliet","owner_url":"/insider/0001431159","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2393.0,"shares_display":"2,393","price_per_share":43.2186,"price_display":"43.22","price_state":"stated","total_value":103422.1098,"total_display":"103,422.11","total_whole":"103,422","shares_owned_after":9167.0,"shares_owned_after_display":"9,167","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-08-14","filed_date":"2020-08-18","scope":"insider"},{"id":2101106,"accession":"0000899243-20-020572","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-20-020572","line_url":"/filing/0000899243-20-020572#line-3","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Inozyme Pharma, Inc.","issuer_ticker":"INZY","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"Longitude Venture Partners III, L.P.; Tammenoms Bakker Juliet; ENRIGHT PATRICK G; Longitude Capital Partners III, LLC","owner_display_name":"Longitude Venture Partners III, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":625000.0,"shares_display":"625,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":10000000.0,"total_display":"10,000,000.00","total_whole":"10,000,000","shares_owned_after":2819379.0,"shares_owned_after_display":"2,819,379","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-07-28","filed_date":"2020-07-28","scope":"insider"},{"id":3111754,"accession":"0000899243-20-019123","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-20-019123","line_url":"/filing/0000899243-20-019123#line-1","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"89bio, Inc.","issuer_ticker":"ETNB","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"ENRIGHT PATRICK G; Longitude Venture Partners III, L.P.; Longitude Capital Partners III, LLC; Tammenoms Bakker Juliet","owner_display_name":"ENRIGHT PATRICK G","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":109090.0,"shares_display":"109,090","price_per_share":27.5,"price_display":"27.50","price_state":"stated","total_value":2999975.0,"total_display":"2,999,975.00","total_whole":"2,999,975","shares_owned_after":2600877.0,"shares_owned_after_display":"2,600,877","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-07-10","filed_date":"2020-07-14","scope":"insider"},{"id":9204689,"accession":"0000899243-19-028574","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-028574","line_url":"/filing/0000899243-19-028574#line-1","is_derivative":false,"issuer_cik":"0001674099","issuer_name":"Molecular Templates, Inc.","issuer_ticker":"MTEM","issuer_name_source":null,"issuer_url":"/issuer/0001674099","owner_cik":null,"owner_name":"ENRIGHT PATRICK G; Longitude Capital Partners III, LLC; Longitude Venture Partners III, L.P.; Tammenoms Bakker Juliet","owner_display_name":"ENRIGHT PATRICK G","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":937500.0,"shares_display":"937,500","price_per_share":8.0,"price_display":"8.00","price_state":"stated","total_value":7500000.0,"total_display":"7,500,000.00","total_whole":"7,500,000","shares_owned_after":4199035.0,"shares_owned_after_display":"4,199,035","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-11-25","filed_date":"2019-12-05","scope":"insider"},{"id":7967368,"accession":"0000899243-19-028242","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-028242","line_url":"/filing/0000899243-19-028242#line-1","is_derivative":false,"issuer_cik":"0001183765","issuer_name":"Molecular Templates, Inc.","issuer_ticker":"MTEM","issuer_name_source":null,"issuer_url":"/issuer/0001183765","owner_cik":null,"owner_name":"Longitude Venture Partners III, L.P.; Longitude Capital Partners III, LLC; Tammenoms Bakker Juliet; ENRIGHT PATRICK G","owner_display_name":"Longitude Venture Partners III, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":937000.0,"shares_display":"937,000","price_per_share":8.0,"price_display":"8.00","price_state":"stated","total_value":7496000.0,"total_display":"7,496,000.00","total_whole":"7,496,000","shares_owned_after":4198535.0,"shares_owned_after_display":"4,198,535","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-11-25","filed_date":"2019-11-27","scope":"insider"},{"id":7939022,"accession":"0000899243-19-027219","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-027219","line_url":"/filing/0000899243-19-027219#line-1","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"89bio, Inc.","issuer_ticker":"ETNB","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"Longitude Capital Partners III, LLC; ENRIGHT PATRICK G; Tammenoms Bakker Juliet; Longitude Venture Partners III, L.P.","owner_display_name":"Longitude Capital Partners III, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":575000.0,"shares_display":"575,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":9200000.0,"total_display":"9,200,000.00","total_whole":"9,200,000","shares_owned_after":575000.0,"shares_owned_after_display":"575,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-11-11","filed_date":"2019-11-13","scope":"insider"},{"id":6011982,"accession":"0000899243-18-028083","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-028083","line_url":"/filing/0000899243-18-028083#line-2","is_derivative":false,"issuer_cik":"0001431159","issuer_name":"Axonics Modulation Technologies, Inc.","issuer_ticker":"AXNX","issuer_name_source":null,"issuer_url":"/issuer/0001431159","owner_cik":"0001431159","owner_name":"Tammenoms Bakker Juliet","owner_display_name":"Tammenoms Bakker Juliet","owner_url":"/insider/0001431159","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":533333.0,"shares_display":"533,333","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":7999995.0,"total_display":"7,999,995.00","total_whole":"7,999,995","shares_owned_after":2933333.0,"shares_owned_after_display":"2,933,333","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-11-02","filed_date":"2018-11-02","scope":"insider"},{"id":6021204,"accession":"0001209191-18-052151","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-052151","line_url":"/filing/0001209191-18-052151#line-1","is_derivative":false,"issuer_cik":"0001183765","issuer_name":"Molecular Templates, Inc.","issuer_ticker":"MTEM","issuer_name_source":null,"issuer_url":"/issuer/0001183765","owner_cik":null,"owner_name":"Longitude Capital Partners III, LLC; ENRIGHT PATRICK G; Tammenoms Bakker Juliet; Longitude Venture Partners III, L.P.","owner_display_name":"Longitude Capital Partners III, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":365000.0,"shares_display":"365,000","price_per_share":5.5,"price_display":"5.50","price_state":"stated","total_value":2007500.0,"total_display":"2,007,500.00","total_whole":"2,007,500","shares_owned_after":3261535.0,"shares_owned_after_display":"3,261,535","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-09-21","filed_date":"2018-09-25","scope":"insider"},{"id":6251178,"accession":"0001140361-18-031069","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001140361-18-031069","line_url":"/filing/0001140361-18-031069#line-3","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Tricida, Inc.","issuer_ticker":"TCDA","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"ENRIGHT PATRICK G; Longitude Capital Partners II, LLC; Longitude Venture Partners II, L.P.; Tammenoms Bakker Juliet","owner_display_name":"ENRIGHT PATRICK G","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":131579.0,"shares_display":"131,579","price_per_share":19.0,"price_display":"19.00","price_state":"stated","total_value":2500001.0,"total_display":"2,500,001.00","total_whole":"2,500,001","shares_owned_after":3019734.0,"shares_owned_after_display":"3,019,734","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-07-02","filed_date":"2018-07-02","scope":"insider"},{"id":6649041,"accession":"0001104659-18-042312","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001104659-18-042312","line_url":"/filing/0001104659-18-042312#line-4","is_derivative":false,"issuer_cik":"0001431159","issuer_name":"Aptinyx Inc.","issuer_ticker":"APTX","issuer_name_source":null,"issuer_url":"/issuer/0001431159","owner_cik":null,"owner_name":"Tammenoms Bakker Juliet; Longitude Venture Partners II, L.P.; Longitude Capital Partners II, LLC","owner_display_name":"Tammenoms Bakker Juliet","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":150000.0,"shares_display":"150,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":2400000.0,"total_display":"2,400,000.00","total_whole":"2,400,000","shares_owned_after":3190079.0,"shares_owned_after_display":"3,190,079","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-25","filed_date":"2018-06-26","scope":"insider"},{"id":6015231,"accession":"0001209191-18-013353","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-013353","line_url":"/filing/0001209191-18-013353#line-1","is_derivative":false,"issuer_cik":"0001431159","issuer_name":"Aimmune Therapeutics, Inc.","issuer_ticker":"AIMT","issuer_name_source":null,"issuer_url":"/issuer/0001431159","owner_cik":"0001431159","owner_name":"Tammenoms Bakker Juliet","owner_display_name":"Tammenoms Bakker Juliet","owner_url":"/insider/0001431159","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9375.0,"shares_display":"9,375","price_per_share":32.0,"price_display":"32.00","price_state":"stated","total_value":300000.0,"total_display":"300,000.00","total_whole":"300,000","shares_owned_after":16651.0,"shares_owned_after_display":"16,651","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-02-22","filed_date":"2018-02-26","scope":"insider"},{"id":4231435,"accession":"0001209191-17-065191","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-17-065191","line_url":"/filing/0001209191-17-065191","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"COLLEGIUM PHARMACEUTICAL, INC","issuer_ticker":"COLL","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"Longitude Capital Associates, L.P.; Longitude Venture Partners L.P.; ENRIGHT PATRICK G; Longitude Capital Partners, LLC; Tammenoms Bakker Juliet","owner_display_name":"Longitude Capital Associates, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000000.0,"shares_display":"1,000,000","price_per_share":17.34,"price_display":"17.34","price_state":"stated","total_value":17340000.0,"total_display":"17,340,000.00","total_whole":"17,340,000","shares_owned_after":2276222.0,"shares_owned_after_display":"2,276,222","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-12-08","filed_date":"2017-12-12","scope":"insider","n_lines":2},{"id":4324397,"accession":"0001209191-17-046462","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-17-046462","line_url":"/filing/0001209191-17-046462#line-2","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Kala Pharmaceuticals, Inc.","issuer_ticker":"KALA","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"ENRIGHT PATRICK G; Longitude Venture Partners II, L.P.; Tammenoms Bakker Juliet; Longitude Capital Partners II, LLC","owner_display_name":"ENRIGHT PATRICK G","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":215000.0,"shares_display":"215,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":3225000.0,"total_display":"3,225,000.00","total_whole":"3,225,000","shares_owned_after":2270946.0,"shares_owned_after_display":"2,270,946","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-07-25","filed_date":"2017-07-27","scope":"insider"},{"id":2968763,"accession":"0001209191-16-152057","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-16-152057","line_url":"/filing/0001209191-16-152057#line-6","is_derivative":false,"issuer_cik":"0001088856","issuer_name":"CORCEPT THERAPEUTICS INC","issuer_ticker":"CORT","issuer_name_source":null,"issuer_url":"/issuer/0001088856","owner_cik":null,"owner_name":"Tammenoms Bakker Juliet; Longitude Venture Partners L.P.; Longitude Capital Partners, LLC; Longitude Capital Associates, L.P.","owner_display_name":"Tammenoms Bakker Juliet","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14451.0,"shares_display":"14,451","price_per_share":9.3869,"price_display":"9.39","price_state":"stated","total_value":135650.0919,"total_display":"135,650.09","total_whole":"135,650","shares_owned_after":13775899.0,"shares_owned_after_display":"13,775,899","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-11-25","filed_date":"2016-11-25","scope":"insider"}],"collapsed":true,"next_cursor":"2016-11-25|2968763","ledger_fault":false,"count":{"value":23,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":11,"open_market":true},{"code":"S","label":"Open-market sale","n":12,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":23},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001380106","name":"RAPID MICRO BIOSYSTEMS, INC.","url":"/issuer/0001380106","role":"Ten percent owner","n_filings":3,"first_seen":"2021-07-20","last_seen":"2026-02-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001861107","name":"Ceribell, Inc.","url":"/issuer/0001861107","role":"Director","n_filings":1,"first_seen":"2024-10-16","last_seen":"2024-10-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001111485","name":"RxSight, Inc.","url":"/issuer/0001111485","role":"Director","n_filings":9,"first_seen":"2021-08-05","last_seen":"2024-05-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001907108","name":"Lexeo Therapeutics, Inc.","url":"/issuer/0001907108","role":"Ten percent owner","n_filings":1,"first_seen":"2023-11-09","last_seen":"2023-11-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001831828","name":"Vera Therapeutics, Inc.","url":"/issuer/0001831828","role":"Ten percent owner","n_filings":3,"first_seen":"2021-05-18","last_seen":"2023-02-08"},{"type":"issuer","type_label":"ISSUER","cik":"0001693011","name":"Inozyme Pharma, Inc.","url":"/issuer/0001693011","role":"Ten percent owner","n_filings":2,"first_seen":"2020-07-28","last_seen":"2022-04-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001290149","name":"Sierra Oncology, Inc.","url":"/issuer/0001290149","role":"Ten percent owner","n_filings":1,"first_seen":"2022-02-02","last_seen":"2022-02-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001827506","name":"Talaris Therapeutics, Inc.","url":"/issuer/0001827506","role":"Ten percent owner","n_filings":1,"first_seen":"2021-05-11","last_seen":"2021-05-11"},{"type":"issuer","type_label":"ISSUER","cik":"0001719395","name":"Eargo, Inc.","url":"/issuer/0001719395","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2020-10-22","last_seen":"2020-10-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001603756","name":"Axonics Modulation Technologies, Inc.","url":"/issuer/0001603756","role":"Director, Ten percent owner","n_filings":3,"first_seen":"2018-11-02","last_seen":"2020-09-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001183765","name":"Molecular Templates, Inc.","url":"/issuer/0001183765","role":"Ten percent owner","n_filings":4,"first_seen":"2018-09-25","last_seen":"2020-09-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001785173","name":"89bio, Inc.","url":"/issuer/0001785173","role":"Ten percent owner","n_filings":2,"first_seen":"2019-11-13","last_seen":"2020-07-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001595585","name":"Tricida, Inc.","url":"/issuer/0001595585","role":"Ten percent owner","n_filings":1,"first_seen":"2018-07-02","last_seen":"2018-07-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001674365","name":"Aptinyx Inc.","url":"/issuer/0001674365","role":"Ten percent owner","n_filings":1,"first_seen":"2018-06-26","last_seen":"2018-06-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001631650","name":"Aimmune Therapeutics, Inc.","url":"/issuer/0001631650","role":"Ten percent owner","n_filings":3,"first_seen":"2015-08-11","last_seen":"2018-02-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001267565","name":"COLLEGIUM PHARMACEUTICAL, INC","url":"/issuer/0001267565","role":"Ten percent owner","n_filings":2,"first_seen":"2015-05-14","last_seen":"2017-12-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001479419","name":"Kala Pharmaceuticals, Inc.","url":"/issuer/0001479419","role":"Ten percent owner","n_filings":1,"first_seen":"2017-07-27","last_seen":"2017-07-27"},{"type":"issuer","type_label":"ISSUER","cik":"0001088856","name":"CORCEPT THERAPEUTICS INC","url":"/issuer/0001088856","role":"Director, Ten percent owner","n_filings":10,"first_seen":"2009-02-10","last_seen":"2016-11-25"},{"type":"issuer","type_label":"ISSUER","cik":"0001434868","name":"Esperion Therapeutics, Inc.","url":"/issuer/0001434868","role":"Ten percent owner","n_filings":4,"first_seen":"2013-07-01","last_seen":"2014-11-19"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001431159","retrieved_at":"2026-08-26T16:17:00+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}